Big Data Analysis of Liver Adverse Reactions Monitoring of Chinese and Western Medicines Based on Age Correction and Risk Warning for Dermatologic Drugs

doi:10.19803/j.1672-8629.20240720

Abstract

Abstract: Objective To explore the relationship between age and the risk of drug-induced liver injury (DILI), and to study the impact of age on the risk of adverse reactions induced by Chinese and Western medicines. Methods Reports about adverse drug reactions related to DILI were retrospectively analyzed, and the number of ADR reports was adjusted demographically based on the data of a census. The way in which the risk of DILI changed with age, the usage of categorized drugs and the characteristics of drugs of special varieties were analyzed. Results After age correction, the incidence of liver injury was found to increase with the age of users of traditional Chinese medicines and Western medicines in particular. Analysis by drug category showed that the risk of DILI increased with age, except for Western medicines used for the nervous system, traditional Chinese medicines and Western medicines for skin diseases. DILI due to traditional Chinese medicines for dermatologic diseases caused a larger number of serious adverse reactions than Western medicines. The underlying diseases of patients were mostly vitiligo, psoriasis and alopecia. Preparations involving Dictamni cortex, Polygonum multiflorum, Psoralea corylifolia were high-risk drugs. Conclusion The risk of DILI is positively correlated with age for most drugs. The risk posed by drugs for DILI and by traditional Chinese medicines for skin diseases deserves more attention so as to prevent the occurrence of serious adverse reactions.

Key words: Adverse Drug Reaction, Drug-Induced Liver Injury, Age, Skin Medicine, Risk Signal

CLC Number:

LONG Minjuan, ZHAO Xu, GUO Longxin, CAI Yuhan, LIN Li, ZHU Shengkai, LIU Wenlong, SONG Haibo, XIAO Xiaohe. Big Data Analysis of Liver Adverse Reactions Monitoring of Chinese and Western Medicines Based on Age Correction and Risk Warning for Dermatologic Drugs[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 271-275.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240720

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I3/271

References

[1] WANG J, SONG H, GE F, et al.Landscape of DILI-Related Adverse Drug Reaction in China Mainland[J].Acta Pharmaceutica Sinica B, 2022, 12(12): 4424-4431.
[2] HE TT, BAI ZF, WANG JB, et al.Phenotypic Characteristics and Toxicological Mechanism of Liver Injury Associated with Chinese Herbal Medicine[J].Journal of Clinical Hepatobiliary Diseases(临床肝胆病杂志),2024, 40(8): 1525-1532.
[3] XIAO XH, BAI ZF, WANG JB, et al.Safety Evaluation and Pharmacovi-gilance of Traditional Chinese Medicine[J] .Chinese Science Bulletin(科学通报),2021, 66(Z1): 407-414.
[4] YU S, LI J, HE T, et al.Age-Related Differences in Drug-Induced Liver Injury: a Retrospective Single-Center Study from a Large Liver Disease Specialty Hospital in China, 2002-2022[J].Hepatology International, 2024, 18(4): 1202-1213.
[5] SHI Q, YANG X, GREENHAW JJ, et al.Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status[J].International Journal of Toxicology, 2017, 36(5): 365-379.
[6] SONG HB, HAN L. Epidemic Characteristics, Risk Factors and Evaluation of Liver Injury with Traditional Chinese Medicine[J].Chinese Journal of Pharmacology and Toxicology(中国药理学与毒理学杂志),2016, 30(4): 291-305.
[7] FARAJ S, KEMP EH, GAWKRODGER DJ.Patho-Immunological Mechanisms of Vitiligo: the Role of the Innate and Adaptive Immunities and Environmental Stress Factors[J].Clinical and Experimental Immunology, 2022, 207(1): 27-43.
[8] XIN Y, YUAN T, WANG J.Circulating Immune Cells and Vitiligo: a Bidirectional Two-Sample Mendelian Randomization Study[J].Frontiers in Immunology, 2024, 15: 1391186.
[9] JIANG J, LU QJ.Research Progress of Immune Dermatology in China[J].Chinese Journal of Immunology(中国免疫学杂志),2024, 40(1): 37-51.
[10] ZHAO LM, MIAO LY.Research Progress and Prospect of Drug-Induced Liver Injury[J].Progress in Pharmaceutical Sciences(药学进展),2023, 47(2): 81-83.
[11] BAI ZF, WANG JB, XIAO XH.Toxicity Cognition Innovation and Safe Precision Drug use of Traditional Chinese Medicine[J].China Journal of Chinese Materia Medica(中国中药杂志),2022, 47(10): 2557-2564.
[12] GAO YJ, ZHAO X, BAI ZF, et al.Prevention and Control of Safety Risks of Traditional Chinese Medicine Based on Indirect Toxicity Cognition[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2021, 18(11): 1004-1008.
[13] LUCENA M I, SANABRIA J, GARCÍA-CORTES M, et al. Drug-Induced Liver Injury in Older People[J].The Lancet. Gastroenterology & Hepatology, 2020, 5(9): 862-874.
[14] SUZUKI A, CHEN CJ. Epidemiology and Risk Determinants of Drug-Induced Liver Injury: Current Knowledge and Future Research Needs[J/OL].Liver International,(2024-11-04)[2024-12-01].https://pubmed.ncbi.nlm.nih.gov/39494620/.
[15] COHEN EB, PATWARDHAN M, RAHEJA R, et al.Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative[J].Drug Safety, 2024, 47(4): 301-319.
[16] CHEN YC, FAN JS, CHEN MH, et al.Risk Factors Associated with Adverse Drug Events among Older Adults in Emergency Department[J].European Journal of Internal Medicine, 2014, 25(1): 49-55.
[17] WANG Y, LIANG J, FANG Y, et al.Burden of Common Neurologic Diseases in Asian Countries, 1990-2019: an Analysis for the Global Burden of Disease Study 2019[J].Neurology, 2023, 100(21): e2141-e2154.
[18] GBD 2017 US Neurological Disorders Collaborators, FEIGIN VL, VOS T, et al. Burden of Neurological Disorders Across the US From 1990-2017: a Global Burden of Disease Study[J].JAMA Neurology, 2021, 78(2): 165-176.
[19] XIONG YT, WANG JF, NIU XX, et al.Autoimmunity Associates with Severity of Illness in Elderly Patients with Drug-Induced Liver Injury[J].Frontiers in Pharmacology, 2023, 14: 1071709.
[20] TAJIRI K, SHIMIZU Y.Liver Physiology and Liver Diseases in the Elderly[J].World Journal of Gastroenterology, 2013, 19(46): 8459-8467.
[21] JIA XC, XU YY, LI YB.Research Progress on Toxicity of Compound Qingdai Preparation and Single Compound Drug[J].Chinese Traditional and Herbal Drugs(中草药),2023, 54(24): 8282-8289.
[22] GAO P, CHANG K, YUAN S, et al.Exploring the Mechanism of Hepatotoxicity Induced by Dictamnus Dasycarpus Based on Network Pharmacology, Molecular Docking and Experimental Pharmacology[J] .Molecules(Basel, Switzerland),2023, 28(13): 5045.
[23] CHANG X, LI G, YANG B, et al.Protection of Schisantherin a Against Dictamnine-Induced Hepatotoxicity: Pharmacokinetic Insights[J].Journal of Applied Toxicology, 2024, 44(4): 501-509.
[24] LUO Q, SHEN Y, ZHAI G, et al.Role of Covalent Modification by Hepatic Aldehydes in Dictamnine-Induced Liver Injury[J].Toxicology Letters, 2024, 392: 12-21.
[25] SHANG H, LIU X, PAN J, et al.Exploring the Mechanism and Phytochemicals in Psoraleae Fructus-Induced Hepatotoxicity based on RNA-seq, in vitro Screening and Molecular Docking[J].Scientific Reports, 2024, 14(1): 1696.
[26] LIU B, FANG S, ZHOU K, et al.Unveiling Hepatotoxicity Distinction of Coumarin-Related Compounds from Glycosides to Aglycones in Fructus Psoraleae by Integrating UPLC-Q-TOF-MS and High Content Analysis[J].Journal of Ethnopharmacology, 2023, 315: 116664.
[27] LI D, LYU Y, SONG Q, et al.Idiosyncratic Liver Injury Induced by Bolus Combination Treatment with Emodin and 2,3,5,4’-tetrahydroxystilbene-2-O-β-D-glucopyranoside in Rats[J].Frontiers in Pharmacology, 2022, 13: 1017741.
[28] CHEN M, SUZUKI A, BORLAK J, et al.Drug-Induced Liver Injury: Interactions between Drug Properties and Host Factors[J].Journal of Hepatology, 2015, 63(2): 503-514.
[29] BAI YP, SONG XJ.Characteristics and Advantages of TCM Clinical Thinking in Dermatology[J].Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine(中国中西医结合皮肤性病学杂志),2019, 18(1): 83-85.